 The European Medicines Agencys CHMP recommended conditional approval of Janssen, a unit of Johnson Johnson NYSE: JNJ, and its partner Legend Biotech Corporations NASDAQ: LEGN CAR-T therapy to treat multiple myeloma. The drug, Carvykti . 